Torrent Pharma Q2 PAT may dip 5.4% YoY to Rs. 190 cr: HDFC Securities

Torrent Pharma-Elder portfolio acquisition | Year: December 2013 | Deal size: USD 323 million Objective: To expand India portfolio and scale up sub-optimal products. Result: Elder's portfolio acquisition turned out to be highly profitable for Torrent, with 23 percent CAGR of Elder’s brands over FY14-17. Torrent, the 12th largest (in terms of IMS sales) pharma players in India increased its market share from 2.0% to 2.7% in the country. (Image: Reuters)

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

HDFC Securities has come out with its second quarter (July-September’ 18) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Torrent Pharma to report net profit at Rs. 190 crore down 5.4% year-on-year (up 18.4% quarter-on-quarter).

Net Sales are expected to increase by 34.6 percent Y-o-Y (up 2.7 percent Q-o-Q) to Rs. 1,920 crore, according to HDFC Securities.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 52.9 percent Y-o-Y (up 5.5 percent Q-o-Q) to Rs. 500 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More